

**Investor Contact:**

Mark Maico  
[ir@bauschhealth.com](mailto:ir@bauschhealth.com)  
(908) 541-2102  
(877) 281-6642 (toll free)

**Media Contact:**

Kevin Wiggins  
[corporate.communications@bauschhealth.com](mailto:corporate.communications@bauschhealth.com)  
(908) 541-3785

**Bausch Health Announces 2023 Annual Meeting of Shareholder Results**

LAVAL, Quebec, May 17, 2023– Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the results of its 2023 annual meeting of shareholders (the “Annual Meeting”).

The 10 directors nominated at the Company’s Annual Meeting held on May 16, 2023, were elected by a vote of the Company’s shareholders. The detailed results of the vote for the election of directors are set out below:

<b>Name</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Thomas J. Appio	190,930,071	2,850,553	69,221,265
Brett M. Icahn	169,686,359	24,094,265	69,221,265
Sarah B. Kavanagh	189,301,790	4,478,834	69,221,265
Steven D. Miller	181,093,705	12,686,919	69,221,265
Dr. Richard C. Mulligan	174,330,012	19,450,612	69,221,265
John A. Paulson	182,711,655	11,068,969	69,221,265
Robert N. Power	183,421,864	10,358,760	69,221,265
Russel C. Robertson	189,249,474	4,531,150	69,221,265
Thomas W. Ross, Sr.	190,210,369	3,570,255	69,221,265
Amy B. Wechsler, M.D.	190,174,239	3,606,385	69,221,265

Shareholders also approved the non-binding advisory vote on the compensation of the Company’s named executive officers and an annual frequency of future advisory votes on the compensation of the Company’s named executive officers approved an amendment to the Company’s 2014 Omnibus Incentive Plan (the “Plan”) to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the Company’s 2024 annual meeting of shareholders.

For the purposes of Toronto Stock Exchange (TSX) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company’s SEDAR profile and on the Company’s website at [www.bauschhealth.com](http://www.bauschhealth.com).

## **About Bausch Health**

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit [www.bauschhealth.com](http://www.bauschhealth.com) and connect with us on [Twitter](#) and [LinkedIn](#).

## **Forward-looking Statements**

This news release may contain forward-looking statements about Bausch Health and Bausch + Lomb, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions, including statements about the timing and details of the future plans for Bausch + Lomb and its future performance. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's and Bausch + Lomb's overall business, including those more fully described in Bausch + Lomb's and Bausch Health's respective filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health and Bausch + Lomb undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###